Business
Biodesix to Present New Data at Two Major Upcoming Scientific Meetings
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentation
About this update from Biodesix, Inc.
[{"type":"image","alt":"Biodesix, Inc.","displaySize":"","headline":null,"caption":"Biodesix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/cd1b6f0f04b27dd51e3e0af52fefc5f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZXm0WIRUy_.i8bpwMH7VDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cd1b6f0f04b27dd51e3e0af52fefc5f0","width":300,"height":110}},"lazy":false},{"type":"text","content":"Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer","length":172,"tagName":"p"},{"type":"text","content":"Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS)","length":166,"tagName":"p"},{"type":"text","content":"LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings.","length":267,"tagName":"p"},{"type":"text","content":"At the 2025 North American Conference on Lung Cancer (NACLC), December 5 - 7, in Chicago, IL, Biodesix will present new findings on its on-market Nodify Lung® tests, with data that spotlight the importance of timely, accurate lung nodule risk classification to support the early detection of lung cancer:","length":304,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Refining Post-test Probability of Lung Cancer Using Post-Market Data from a Blood-based Biomarker Test in Pulmonary Nodule Patients.Authors: Michael N. Kammer, PhD (Biodesix Head of Radiomics and Presenter); Trevor Pitcher, PhD; Gary Pestano, PhD; Laura Peek, PhD; James R. Jett, MD, MS, FCCP; Steven C. Springmeyer, MD, FCCP.","length":327,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":327,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Modeling the Impact of an Autoantibody Blood Test for Lung Cancer on Time to Diagnosis in Pulmonary Nodule Assessment: A Multi-Cohort Analysis.Authors: Kathryn Long, MD (Presenter); Gerard A. Silvestri, M...